Welcome guest, Login | Register


Valentin Derangère


Ph.D. in Life Sciences and Molecular Biology, Dijon, France, 2014

Current position

Cellular Biologist in Centre GF Leclerc, Dijon, France

Publications (since 2013)

  1. Thibaudin, M., Chaix, M., Boidot, R., Vegran, F., Derangere, V., Limagne, E., Berger, H., Ladoire, S., Apetoh, L. and Ghiringhelli, F. (2016). Human ectonucleotidase-expressing CD25High Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Oncoimmunology 5(1): e1055444.
  2. Fluckiger, A., Dumont, A., Derangere, V., Rebe, C., de Rosny, C., Causse, S., Thomas, C., Apetoh, L., Hichami, A., Ghiringhelli, F. and Rialland, M. (2016). Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFα. Oncogene. (Epub ahead of print)
  3. Derangere, V., Fumet, J. D., Boidot, R., Bengrine, L., Limagne, E., Chevriaux, A., Vincent, J., Ladoire, S., Apetoh, L., Rebe, C. and Ghiringhelli, F. (2016). Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget 7(8): 9309-9321.
  4. Courtaut, F., Derangere, V., Chevriaux, A., Ladoire, S., Cotte, A. K., Arnould, L., Boidot, R., Rialland, M., Ghiringhelli, F. and Rebe, C. (2015). Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization. Oncotarget 6(29): 26651-26662.
  5. Bruchard, M., Rebe, C., Derangere, V., Togbe, D., Ryffel, B., Boidot, R., Humblin, E., Hamman, A., Chalmin, F., Berger, H., Chevriaux, A., Limagne, E., Apetoh, L., Vegran, F. and Ghiringhelli, F. (2015). The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol 16(8): 859-870.
  6. Pages, P. B., Derangere, V., Bouchot, O., Magnin, G., Charon-Barra, C., Lokiec, F., Ghiringhelli, F. and Bernard, A. (2015). Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs. Eur J Cardiothorac Surg 48(2): 228-235.
  7. Derangere, V., Chevriaux, A., Courtaut, F., Bruchard, M., Berger, H., Chalmin, F., Causse, S. Z., Limagne, E., Vegran, F., Ladoire, S., Simon, B., Boireau, W., Hichami, A., Apetoh, L., Mignot, G., Ghiringhelli, F. and Rebe, C. (2014). Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells. Cell Death Differ 21(12): 1914-1924.
  8. Vegran, F., Berger, H., Boidot, R., Mignot, G., Bruchard, M., Dosset, M., Chalmin, F., Rebe, C., Derangere, V., Ryffel, B., Kato, M., Prevost-Blondel, A., Ghiringhelli, F. and Apetoh, L. (2014). The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 15(8): 758-766.
  9. Berger, H., Vegran, F., Chikh, M., Gilardi, F., Ladoire, S., Bugaut, H., Mignot, G., Chalmin, F., Bruchard, M., Derangere, V., Chevriaux, A., Rebe, C., Ryffel, B., Pot, C., Hichami, A., Desvergne, B., Ghiringhelli, F. and Apetoh, L. (2013). SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth. Cancer Res 73(12): 3578-3590.
  10. Ishibashi, M., Filomenko, R., Rebe, C., Chevriaux, A., Varin, A., Derangere, V., Bessede, G., Gambert, P., Lagrost, L. and Masson, D. (2013). Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation. Biochem Pharmacol 86(1): 122-129.
  11. Bruchard, M., Mignot, G., Derangere, V., Chalmin, F., Chevriaux, A., Vegran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., Kanellopoulos, J., Martin, F., Rebe, C., Apetoh, L. and Ghiringhelli, F. (2013). Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1): 57-64.
Protocols by Valentin Derangère
  1. Proximity Ligation Assay (PLA) Protocol Using Duolink® for T Cells
  2. Liquid luminescent DNA-precipitation Assay